Novartis (NVS) Stock Forecast, Price Target & Predictions
NVS Stock Forecast
Novartis stock forecast is as follows: an average price target of $116.33 (represents a 5.26% upside from NVS’s last price of $110.52) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.
NVS Price Target
The average price target for Novartis (NVS) is $116.33 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $121.00 to $108.00. This represents a potential 5.26% upside from NVS's last price of $110.52.
NVS Analyst Ratings
According to 9 Wall Street analysts, Novartis's rating consensus is 'Hold'. The analyst rating breakdown for NVS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (33.33%), 6 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Novartis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Etzer Darout | BMO Capital | $120.00 | $109.91 | 9.18% | 8.58% |
| Sep 05, 2024 | James Quigley | Goldman Sachs | $121.00 | $119.38 | 1.36% | 9.48% |
| Jul 19, 2024 | Etzer Darout | BMO Capital | $118.00 | $106.13 | 11.18% | 6.77% |
| Apr 23, 2024 | Wan Nurhayati | CFRA | $108.00 | $97.27 | 11.03% | -2.28% |
The latest Novartis stock forecast, released on Oct 30, 2024 by Etzer Darout from BMO Capital, set a price target of $120.00, which represents a 9.18% increase from the stock price at the time of the forecast ($109.91), and a 8.58% increase from NVS last price ($110.52).
Novartis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $120.00 | $120.50 | $116.75 |
| Last Closing Price | $110.52 | $110.52 | $110.52 |
| Upside/Downside | 8.58% | 9.03% | 5.64% |
In the current month, the average price target of Novartis stock is $120.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 8.58% increase as opposed to Novartis's last price of $110.52. This month's average price target is down -0.41% compared to last quarter, and up 2.78% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Sep 05, 2024 | Goldman Sachs | Buy | Neutral | Downgrade |
| Sep 02, 2024 | Jefferies | Buy | Hold | Downgrade |
| Jul 19, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Jul 19, 2024 | Deutsche Bank | - | Hold | Downgrade |
| Jul 12, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 11, 2024 | Oddo BHF | - | Outperform | Upgrade |
| Jul 02, 2024 | Jefferies | Buy | Buy | Hold |
| May 30, 2024 | Goldman Sachs | - | Buy | Initialise |
| Apr 24, 2024 | UBS | Buy | Buy | Hold |
Novartis's last stock rating was published by BMO Capital on Oct 30, 2024. The company gave NVS a "Market Perform" rating, the same as its previous rate.
Novartis Financial Forecast
Novartis Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $13.21B | $13.09B | $12.84B | $13.09B | $12.81B | $13.52B | $13.37B | $13.29B | $12.69B | $13.03B | $12.54B | $11.62B | $12.71B | $12.72B | $12.48B | $12.02B | $11.46B | $12.93B | $11.79B |
| Avg Forecast | $12.08B | $12.56B | $12.81B | $12.44B | $12.95B | $12.79B | $12.45B | $11.44B | $11.88B | $12.42B | $13.47B | $12.72B | $13.22B | $12.88B | $12.88B | $12.62B | $13.33B | $13.06B | $12.55B | $12.50B | $12.90B | $12.60B | $11.84B | $12.00B | $12.33B | $11.70B | $11.49B | $11.09B | $12.93B | $11.57B |
| High Forecast | $12.35B | $12.84B | $13.10B | $12.44B | $13.42B | $12.86B | $12.49B | $11.44B | $12.25B | $12.65B | $13.77B | $13.00B | $13.51B | $12.88B | $12.88B | $12.62B | $13.33B | $13.06B | $12.55B | $12.50B | $12.90B | $12.60B | $11.84B | $12.00B | $12.33B | $11.70B | $11.49B | $11.09B | $15.51B | $13.89B |
| Low Forecast | $11.94B | $12.41B | $12.66B | $12.29B | $12.70B | $12.72B | $12.41B | $11.44B | $11.59B | $12.28B | $13.31B | $12.56B | $13.06B | $12.88B | $12.88B | $12.62B | $13.33B | $13.06B | $12.55B | $12.50B | $12.90B | $12.60B | $11.84B | $12.00B | $12.33B | $11.70B | $11.49B | $11.09B | $10.34B | $9.26B |
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.99% | 1.00% | 1.02% | 1.02% | 1.01% | 1.02% | 1.06% | 1.02% | 1.01% | 0.99% | 0.98% | 1.06% | 1.03% | 1.07% | 1.05% | 1.03% | 1.00% | 1.02% |
Novartis's average Quarter revenue forecast for Jun 23 based on 1 analysts is $13.47B, with a low forecast of $13.31B, and a high forecast of $13.77B. NVS's average Quarter revenue forecast represents a 2.02% increase compared to the company's last Quarter revenue of $13.21B (Mar 23).
Novartis EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $4.95B | $3.91B | $4.16B | $4.05B | $4.28B | $18.68B | $4.88B | $5.15B | $4.35B | $4.37B | $4.36B | $4.21B | $4.27B | $3.90B | $4.03B | $8.57B | $3.71B | $2.63B | $3.90B |
| Avg Forecast | $4.84B | $5.03B | $5.13B | $4.98B | $5.19B | $5.12B | $4.99B | $5.18B | $4.76B | $4.97B | $5.40B | $4.71B | $5.30B | $5.16B | $5.16B | $4.28B | $5.34B | $5.23B | $5.03B | $4.54B | $5.17B | $5.05B | $4.74B | $3.68B | $4.94B | $4.69B | $4.60B | $3.55B | $2.63B | $3.83B |
| High Forecast | $4.95B | $5.14B | $5.25B | $4.99B | $5.38B | $5.15B | $5.00B | $6.21B | $4.91B | $5.07B | $5.52B | $5.65B | $5.41B | $5.16B | $5.16B | $5.13B | $5.34B | $5.23B | $5.03B | $5.45B | $5.17B | $5.05B | $4.74B | $4.42B | $4.94B | $4.69B | $4.60B | $4.25B | $3.16B | $4.60B |
| Low Forecast | $4.78B | $4.97B | $5.07B | $4.92B | $5.09B | $5.10B | $4.97B | $4.14B | $4.64B | $4.92B | $5.33B | $3.76B | $5.23B | $5.16B | $5.16B | $3.42B | $5.34B | $5.23B | $5.03B | $3.63B | $5.17B | $5.05B | $4.74B | $2.94B | $4.94B | $4.69B | $4.60B | $2.84B | $2.10B | $3.07B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 0.74% | 0.81% | 0.78% | 1.00% | 3.50% | 0.93% | 1.02% | 0.96% | 0.85% | 0.86% | 0.89% | 1.16% | 0.79% | 0.86% | 1.86% | 1.05% | 1.00% | 1.02% |
1 analysts predict NVS's average Quarter EBITDA for Jun 23 to be $5.40B, with a high of $5.52B and a low of $5.33B. This is 9.11% upper than Novartis's previous annual EBITDA (Mar 23) of $4.95B.
Novartis Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $2.29B | $1.47B | $1.57B | $1.69B | $2.22B | $16.31B | $2.76B | $2.90B | $2.06B | $2.09B | $1.94B | $1.87B | $2.18B | $1.13B | $2.04B | $6.80B | $1.77B | $2.02B | $1.67B |
| Avg Forecast | $3.97B | $4.22B | $4.39B | $3.95B | $3.73B | $3.93B | $3.75B | $2.69B | $3.35B | $3.38B | $3.32B | $2.44B | $18.44B | $3.01B | $2.92B | $2.22B | $2.75B | $3.17B | $3.02B | $2.15B | $2.65B | $2.80B | $2.57B | $1.87B | $2.55B | $2.57B | $2.35B | $1.69B | $2.02B | $1.64B |
| High Forecast | $4.09B | $4.34B | $4.51B | $3.97B | $3.93B | $3.95B | $3.75B | $3.23B | $3.61B | $3.48B | $3.42B | $2.93B | $22.12B | $3.01B | $2.92B | $2.67B | $2.75B | $3.17B | $3.02B | $2.58B | $2.65B | $2.80B | $2.57B | $2.25B | $2.55B | $2.57B | $2.35B | $2.03B | $2.43B | $1.96B |
| Low Forecast | $3.91B | $4.15B | $4.32B | $3.93B | $3.59B | $3.91B | $3.75B | $2.15B | $3.13B | $3.36B | $3.27B | $1.96B | $14.75B | $3.01B | $2.92B | $1.78B | $2.75B | $3.17B | $3.02B | $1.72B | $2.65B | $2.80B | $2.57B | $1.50B | $2.55B | $2.57B | $2.35B | $1.35B | $1.62B | $1.31B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.08% | 0.52% | 0.58% | 1.00% | 5.93% | 0.87% | 0.96% | 0.96% | 0.79% | 0.69% | 0.73% | 1.16% | 0.44% | 0.79% | 2.90% | 1.05% | 1.00% | 1.02% |
Novartis's average Quarter net income forecast for Jun 23 is $3.32B, with a range of $3.27B to $3.42B. NVS's average Quarter net income forecast represents a 44.91% increase compared to the company's last Quarter net income of $2.29B (Mar 23).
Novartis SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $3.44B | $3.75B | $3.41B | $3.58B | $3.51B | $3.98B | $3.62B | $3.75B | $3.53B | $3.92B | $3.42B | $3.37B | $3.49B | $3.90B | $3.55B | $3.58B | $3.33B | $3.92B | $3.47B |
| Avg Forecast | $3.39B | $3.53B | $3.60B | $3.49B | $3.64B | $3.59B | $3.50B | $4.25B | $3.34B | $3.49B | $3.78B | $3.86B | $4.51B | $3.62B | $3.62B | $3.51B | $3.74B | $3.67B | $3.53B | $3.68B | $3.62B | $3.54B | $3.33B | $3.00B | $3.46B | $3.29B | $3.23B | $3.19B | $3.92B | $3.41B |
| High Forecast | $3.47B | $3.61B | $3.68B | $3.50B | $3.77B | $3.61B | $3.51B | $5.10B | $3.44B | $3.55B | $3.87B | $4.64B | $5.41B | $3.62B | $3.62B | $4.21B | $3.74B | $3.67B | $3.53B | $4.42B | $3.62B | $3.54B | $3.33B | $3.60B | $3.46B | $3.29B | $3.23B | $3.82B | $4.71B | $4.09B |
| Low Forecast | $3.35B | $3.49B | $3.56B | $3.45B | $3.57B | $3.57B | $3.49B | $3.40B | $3.26B | $3.45B | $3.74B | $3.09B | $3.60B | $3.62B | $3.62B | $2.81B | $3.74B | $3.67B | $3.53B | $2.95B | $3.62B | $3.54B | $3.33B | $2.40B | $3.46B | $3.29B | $3.23B | $2.55B | $3.14B | $2.73B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 0.83% | 0.94% | 0.99% | 1.00% | 1.06% | 0.99% | 1.06% | 0.96% | 1.08% | 0.97% | 1.01% | 1.16% | 1.13% | 1.08% | 1.11% | 1.05% | 1.00% | 1.02% |
Novartis's average Quarter SG&A projection for Jun 23 is $3.78B, based on 1 Wall Street analysts, with a range of $3.74B to $3.87B. The forecast indicates a 9.93% rise compared to NVS last annual SG&A of $3.44B (Mar 23).
Novartis EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $1.09 | $0.69 | $0.73 | $0.77 | $1.00 | $7.29 | $1.23 | $1.29 | $0.91 | $0.92 | $0.85 | $0.82 | $0.96 | $0.50 | $0.90 | $2.94 | $0.77 | $0.87 | $0.70 |
| Avg Forecast | $1.96 | $2.08 | $2.17 | $1.95 | $1.84 | $1.94 | $1.85 | $1.68 | $1.65 | $1.67 | $1.64 | $1.45 | $1.35 | $1.47 | $1.43 | $1.38 | $1.34 | $1.55 | $1.47 | $1.46 | $1.30 | $1.37 | $1.26 | $1.32 | $1.25 | $1.26 | $1.15 | $1.05 | $1.28 | $1.09 |
| High Forecast | $2.02 | $2.14 | $2.23 | $1.96 | $1.94 | $1.95 | $1.85 | $1.73 | $1.78 | $1.71 | $1.69 | $1.46 | $1.38 | $1.47 | $1.43 | $1.40 | $1.34 | $1.55 | $1.47 | $1.46 | $1.30 | $1.37 | $1.26 | $1.32 | $1.25 | $1.26 | $1.15 | $1.05 | $1.54 | $1.31 |
| Low Forecast | $1.93 | $2.05 | $2.13 | $1.94 | $1.77 | $1.93 | $1.85 | $1.63 | $1.54 | $1.66 | $1.61 | $1.44 | $1.33 | $1.47 | $1.43 | $1.35 | $1.34 | $1.55 | $1.47 | $1.46 | $1.30 | $1.37 | $1.26 | $1.32 | $1.25 | $1.26 | $1.15 | $1.05 | $1.02 | $0.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.51% | 0.50% | 0.54% | 0.73% | 5.42% | 0.79% | 0.88% | 0.62% | 0.71% | 0.62% | 0.65% | 0.73% | 0.40% | 0.72% | 2.56% | 0.73% | 0.68% | 0.64% |
According to 1 Wall Street analysts, Novartis's projected average Quarter EPS for Jun 23 is $1.64, with a low estimate of $1.61 and a high estimate of $1.69. This represents a 50.39% increase compared to NVS previous annual EPS of $1.09 (Mar 23).
Novartis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $27.76 | $44.76 | 61.24% | Hold |
| GSK | GSK | $36.97 | $58.00 | 56.88% | Hold |
| MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
| AZN | AstraZeneca | $71.43 | $84.33 | 18.06% | Buy |
| BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
| JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
| SNY | Sanofi | $52.95 | $57.36 | 8.33% | Buy |
| NVS | Novartis | $110.52 | $116.33 | 5.26% | Hold |
| LLY | Eli Lilly and Company | $806.14 | $782.65 | -2.91% | Buy |
| GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
| ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
NVS Forecast FAQ
Is Novartis a good buy?
No, according to 9 Wall Street analysts, Novartis (NVS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 33.33% of NVS's total ratings.
What is NVS's price target?
Novartis (NVS) average price target is $116.33 with a range of $108 to $121, implying a 5.26% from its last price of $110.52. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Novartis stock go up soon?
According to Wall Street analysts' prediction for NVS stock, the company can go up by 5.26% (from the last price of $110.52 to the average price target of $116.33), up by 9.48% based on the highest stock price target, and down by -2.28% based on the lowest stock price target.
Can Novartis stock reach $200?
NVS's average twelve months analyst stock price target of $116.33 does not support the claim that Novartis can reach $200 in the near future.
What is Novartis's current price target trend?
1 Wall Street analyst forecast a $120 price target for Novartis (NVS) this month, up 8.58% from its last price of $110.52. Compared to the last 3 and 12 months, the average price target increased by 9.03% and increased by 5.64%, respectively.
What are Novartis's analysts' financial forecasts?
Novartis's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $49.63B (high $50.22B, low $49.27B), average EBITDA is $20.48B (high $21.75B, low $19.29B), average net income is $14.1B (high $14.86B, low $13.4B), average SG&A $14.98B (high $15.99B, low $14.03B), and average EPS is $7.31 (high $7.47, low $7.17). NVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $49.9B (high $50.73B, low $49.3B), average EBITDA is $19.99B (high $20.32B, low $19.75B), average net income is $16.53B (high $16.91B, low $16.31B), average SG&A $14.02B (high $14.25B, low $13.85B), and average EPS is $8.15 (high $8.34, low $8.05).
Did the NVS's actual financial results beat the analysts' financial forecasts?
Based on Novartis's last annual report (Dec 2022), the company's revenue was $51.83B, beating the average analysts forecast of $51.6B by 0.44%. Apple's EBITDA was $16.39B, missing the average prediction of $19.9B by -17.62%. The company's net income was $6.96B, missing the average estimation of $26.59B by -73.84%. Apple's SG&A was $14.25B, missing the average forecast of $15.25B by -6.56%. Lastly, the company's EPS was $3.19, missing the average prediction of $5.62 by -43.24%. In terms of the last quarterly report (Mar 2023), Novartis's revenue was $13.21B, beating the average analysts' forecast of $12.72B by 3.86%. The company's EBITDA was $4.95B, beating the average prediction of $4.71B by 5.13%. Novartis's net income was $2.29B, missing the average estimation of $2.44B by -6.19%. The company's SG&A was $3.44B, missing the average forecast of $3.86B by -10.88%. Lastly, the company's EPS was $1.09, missing the average prediction of $1.45 by -24.94%